Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

Breast cancer drug Enhertu shows impressive results

by Gina Vitale
June 11, 2022 | A version of this story appeared in Volume 100, Issue 21

 

Enhertu, a drug for people with HER2-low metastatic breast cancer, showed positive results in a Phase 3 trial. The antibody-drug conjugate, a joint effort of AstraZeneca and Daiichi Sankyo, reduced the risk of disease progression or death by 50% compared with chemotherapy. Shanu Modi, the trial’s principal investigator, said in a press release that this is the first demonstration of HER2-directed therapy providing “a survival benefit” to people with low HER2 expression.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.